Literature DB >> 12648580

Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach.

Akiko Horiuchi1, Kazuko Itoh, Motohiko Shimizu, Ikuko Nakai, Teruyuki Yamazaki, Kaoru Kimura, Akihiko Suzuki, Isao Shiozawa, Noritane Ueda, Ikuo Konishi.   

Abstract

OBJECTIVE: The natural history of the development of ovarian carcinoma is not known. It also remains undetermined whether ovarian carcinomas develop from benign and/or borderline malignant tumors or arise de novo from the ovarian surface epithelium.
METHODS: To address these issues clinicopathologically, we reviewed the clinical charts of 543 patients with epithelial ovarian carcinoma and 252 patients with borderline tumors who underwent laparotomy at seven hospitals and collected patients whose clinical and transvaginal ultrasonography (USG) findings for adnexal regions 12 months or fewer prior to the surgery were available. Histological slides of the resected specimens were reexamined concerning the diagnosis and histological grade, as well as the presence or absence of benign- or borderline-like lesions adjacent to the carcinoma.
RESULTS: Forty-nine patients had had gynecological examination with transvaginal USG 12 months or fewer prior to laparotomy. Among them, 35 had carcinomas (11 serous, 6 mucinous, 8 clear cell, 10 endometrioid) and 14 had borderline tumors (8 serous, 6 mucinous). Of the 35 patients with carcinoma, 19 (54%) had been followed up for benign-appearing cysts or endometriotic cysts. In these cases, serial USG examinations revealed an increase in size and/or appearance of the solid part of the cyst. In the remaining 16 (46%), however, there had been no apparent abnormalities in USG, and such cases occurred most frequently for serous carcinomas.
CONCLUSIONS: Our findings suggest that approximately half of ovarian carcinomas develop secondarily from preexisting, benign-appearing cysts or endometriotic cysts, whereas the remaining half seem to develop suddenly from a normal-appearing ovary. This appears to be consistent with two possible pathways of ovarian carcinoma development; adenoma-carcinoma sequence and de novo carcinogenesis.

Entities:  

Mesh:

Year:  2003        PMID: 12648580     DOI: 10.1016/s0090-8258(02)00104-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

Review 1.  Contemporary progress in ovarian cancer screening.

Authors:  Christine S Walsh; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 2.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

4.  A survey of the practice patterns of gynecologic oncologists dealing with hereditary cancer patients in Japan.

Authors:  Noriko Tanabe; Ayumi Shikama; Hiroko Bando; Toyomi Satoh; Chikako Shimizu
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

Review 5.  MicroRNA and ovarian cancer.

Authors:  David C Corney; Alexander Yu Nikitin
Journal:  Histol Histopathol       Date:  2008-09       Impact factor: 2.303

Review 6.  Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts.

Authors:  Kosuke Murakami; Yasushi Kotani; Reona Shiro; Hisamitsu Takaya; Hidekatsu Nakai; Noriomi Matsumura
Journal:  Int J Clin Oncol       Date:  2019-08-31       Impact factor: 3.402

7.  D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD.

Authors:  Ekambaram Ganapathy; Feng Su; David Meriwether; Asokan Devarajan; Victor Grijalva; Feng Gao; Arnab Chattopadhyay; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Int J Cancer       Date:  2011-05-26       Impact factor: 7.396

Review 8.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 9.  Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.

Authors:  Hiroshi Kobayashi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.